About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). Spinal cord injury is a devastating global health issue with profound implications for both morta ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engage in a capital raising activities for the immediate future. Following on from its news yesterday of the discovery of new immune biomarkers in patients with non-active seconda ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute substantially t ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists discontinuation. This advan ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled "Immune mechanisms and shared immune targets in neurodegenerative diseases" was published in Nature Reviews Neurology, highlighting the therapeutic potential of intranasal ...

Core Article Summary - The article highlights the therapeutic potential of intranasal Foralumab, a fully human anti-CD3 monoclonal antibody, for treating neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer’s disease, ALS, and Parkinson’s disease [1][8] - Foralumab works by dampening microglial activation, a key driver of disease in these neurological conditions, and has shown no apparent side effects with easy administration [1] - The review article emphasizes the role of the immune system in neurodegenerative diseases, with microglia being a common therapeutic target [4][9] Clinical Development and Trials - Foralumab is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis (NCT06292923), with 10 patients already dosed in an Expanded Access Program showing improvement or stability within 6 months [5] - The FDA has allowed an additional 20 patients to be enrolled in the Expanded Access Program [5] - The Phase 2 trial for non-active SPMS began screening patients in November 2023 [2] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulation therapies using alternative drug delivery technologies, such as intranasal administration [6] - The company’s lead candidate, intranasal Foralumab, is the only fully human anti-CD3 monoclonal antibody in clinical development and has demonstrated a favorable safety profile and clinical response in studies [6] - Tiziana’s technology for alternative routes of immunotherapy has been patented, with several applications pending, enabling broad pipeline applications [6] Scientific Insights - The review article discusses how microglia, monocytes, and T cells contribute to the pathogenesis of neurodegenerative diseases and their potential as shared therapeutic targets [9] - The microbiome is highlighted as an emerging therapeutic target that indirectly modulates the immune system [9] - Foralumab modulates T cell function by binding to the T cell receptor, dampening inflammation and suppressing effector features in immune cells [10] Industry Implications - Immunotherapeutic approaches targeting the adaptive and innate immune systems are being explored for the treatment of neurological diseases, with common targets and approaches across diseases [4] - The intranasal delivery of Foralumab represents a promising therapeutic avenue for patients with limited treatment options, particularly in progressive MS and other neurological diseases [1][6]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...